Real‐world treatment patterns and outcomes among patients with immune thrombocytopenia ( ITP ) who switched treatment from eltrombopag or romiplostim to avatrombopag in the United States: Results from the REAL ‐ AVA 3.5 study
British Journal of Haematology · 2026-06 · 208 (6) · 2185-2193
DOI: 10.1111/bjh.70531 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 14.05.2026. Verfasst von Caroline Piatek und 8 weiteren Autor:innen. Beteiligte Einrichtung: University of Southern California, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Benzoates, Hydrazines, Purpura, Thrombocytopenic, Idiopathic, Pyrazoles. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Swedish Orphan Biovitrum.
Abstract (Originalsprache)
Real‐world data on treatment response after switching between thrombopoietin receptor agonists are limited for patients with immune thrombocytopenia (ITP). The objective of this study is to describe treatment patterns and outcomes in patients with primary ITP who switched from eltrombopag (ELT) or romiplostim (ROMI) to avatrombopag (AVA). We conducted a retrospective chart review study of adults with primary ITP who initiated ELT or ROMI on or after 1 July 2019, switched to AVA within 30 days of ELT/ROMI discontinuation and had ≥6 months follow‐up after AVA initiation. Patients were followed from AVA initiation until last contact, death or study end (21 March 2025), whichever occurred earliest. Response was defined as achieving ≥1 platelet count (PC) of ≥30 × 10 9 /L, ≥50 × 10 9 /L or ≥100 × 10 9 /L in the absence of rescue therapy. Response durability was the percentage of time on AVA with PCs above the response threshold among responders. Patients ( N = 201) most commonly discontinued ELT/ROMI due to lack of efficacy (59.2%). Among patients with baseline PCs
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Southern California, Los Angeles, California, USA.
- Sobi Inc., Waltham, Massachusetts, USA.
- Cardinal Health, Dublin, Ohio, USA.
- University of Virginia, Charlottesville, Virginia, USA.
ORCID-Profile: Caroline Piatek, Michael Vredenburg
Förderung
- Swedish Orphan Biovitrum
Zitieren
APA
Piatek, C., Oladapo, A., Kolodny, S., Vredenburg, M., Lucht, S., Bland, E., Pathak, P., Feinberg, B., & Maitland, H. (2026). Real‐world treatment patterns and outcomes among patients with immune thrombocytopenia ( ITP ) who switched treatment from eltrombopag or romiplostim to avatrombopag in the United States: Results from the REAL ‐ AVA 3.5 study. British Journal of Haematology, 208(6), 2185-2193. https://doi.org/10.1111/bjh.70531
Vancouver
Piatek C, Oladapo A, Kolodny S, Vredenburg M, Lucht S, Bland E, et al. Real‐world treatment patterns and outcomes among patients with immune thrombocytopenia ( ITP ) who switched treatment from eltrombopag or romiplostim to avatrombopag in the United States: Results from the REAL ‐ AVA 3.5 study. British Journal of Haematology. 2026;208(6):2185-2193. doi:10.1111/bjh.70531
BibTeX
@article{Piatek2026,
author = {Piatek, Caroline and Oladapo, Abiola and Kolodny, Scott and Vredenburg, Michael and Lucht, Sarah and Bland, Emily and Pathak, Prathamesh and Feinberg, Bruce and Maitland, Hillary},
title = {Real‐world treatment patterns and outcomes among patients with immune thrombocytopenia ( ITP ) who switched treatment from eltrombopag or romiplostim to avatrombopag in the United States: Results from the REAL ‐ AVA 3.5 study},
journal = {British Journal of Haematology},
year = {2026},
volume = {208},
number = {6},
pages = {2185--2193},
doi = {10.1111/bjh.70531}
}
EUVIMED